focus -WSS

focus

author：knowledge 2025-10-02 00:53:39 - browse：722

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： With clinical trial data readouts, here's how to spot spin

leisure time

WSS

FDA's Woodcock to retire early next year

Readout LOUD podcast: A CRISPR milestone, biotech mixology

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Takeda, Janssen join wearable maker to measure scratching

FDA investigates CAR

Hospitals look to new technology to keep health care workers safe

focus

focus

hotspot

Trump demands the U.S. pay no more for drugs than other countries … again

Flagship Pioneering launches a new biotech in two countries

At least 13 dead in Texas as scorching temps continue

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Tori Bowie and the unacceptable rates of Black maternal death

Will the market for weight loss drugs really reach $100 billion?

After affirmative action ruling, medical educators look to 'holistic review'

Will the market for weight loss drugs really reach $100 billion?

BioMarin wins approval for gene therapy to treat hemophilia A

What to do when lifesaving products contribute to climate change

hotspot

David Sabatini, ex

FDA's Woodcock to retire early next year

Cigna, Humana reportedly in talks to merge

Ransomware attacks on hospitals: Study outlines patient impact

Astellas still sees hope in its gene therapy after four deaths

Hospitals look to new technology to keep health care workers safe

hotspot

focus

leisure time

explore